CASI PHARMACEUTICALS, INC. Income (Loss) from Equity Method Investments
CASI PHARMACEUTICALS, INC. (CASIF) reported Income (Loss) from Equity Method Investments of -$2.19 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-05-15
| Period end | Income (Loss) from Equity Method Investments 12 month |
|---|---|
| 2025-12-31 | -$2.19M 20-F · filed 2026-05-15 |
| 2024-12-31 | -$1.19M 20-F · filed 2026-05-15 |
| 2023-12-31 | -$48.00K 20-F · filed 2026-05-15 |
| 2022-12-31 | -$846.00K 20-F · filed 2025-03-31 |